TY - JOUR T1 - The Glutamatergic System Expression in Human PC-3 and LNCaP Prostate Cancer Cells JF - Anticancer Research JO - Anticancer Res SP - 371 LP - 377 VL - 29 IS - 1 AU - NIKOLAOS PISSIMISSIS AU - EFSTATHIA PAPAGEORGIOU AU - PETER LEMBESSIS AU - ATHANASIOS ARMAKOLAS AU - MICHAEL KOUTSILIERIS Y1 - 2009/01/01 UR - http://ar.iiarjournals.org/content/29/1/371.abstract N2 - Background: The glutamatergic system (Glu system) comprises the Glu receptors (GluRs), the Glu transporters (GluTs) and glutamine synthetase (GS). Materials and Methods: Using PCR-based detection and Western blot analysis, the expression of Glu system components was assessed in human androgen-independent PC-3 and androgen-dependent LNCaP prostate cancer cells. Results: iGluRs, such as NR1, NR2A, NR2C, NR2D and NR3B; mGLuRs such as mGluR1, mGluR2, mGluR3, mGluR4 and mGluR5; GluTs such as EAAT1, EAAT2, EAAT3 and EAAT5; and GS mRNA were steadily expressed in both cell lines. In addition, NR3A, mGluR6, mGluR8 and EAAT4 mRNA were differentially expressed in PC-3 and LNCaP cells. mGluR7 and EAAT4 mRNA expression was induced and mGluR8 was silenced by dihydrotestosterone (DHT) treatment in LNCaP cells. GS, EAAT1 and mGLuR5 were also detected at the protein level in both PC-3 and LNCAP cells. Conclusion: These data suggest that the Glu system could be an important regulator of prostate cancer cell biology. Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -